Welcome to our dedicated page for Quince news (Ticker: QNCX), a resource for investors and traders seeking the latest updates and insights on Quince stock.
Quince Therapeutics reports biotechnology, clinical-development and corporate restructuring updates tied to its rare-disease focus. The company’s AIDE technology is a drug/device platform designed to encapsulate drugs in a patient’s own red blood cells, and its lead asset eDSP has been studied in Ataxia-Telangiectasia, a rare pediatric neurodegenerative disease.
Recurring news includes eDSP clinical data, scientific presentations and publications, business updates, financial results, debt-settlement activity and the company’s evaluation of strategic alternatives. Recent company communications also reflect the decision to cease clinical development of eDSP following Phase 3 NEAT trial results and to preserve cash while reviewing available corporate options.
Cortexyme, Inc. will officially change its name to Quince Therapeutics on August 1, 2022, with the ticker symbol transitioning from CRTX to QNCX on the Nasdaq Global Select Market. This change aims to reflect the company’s updated growth strategy and development pipeline, which will be detailed in an upcoming news release. The current stock certificates remain valid and require no exchange. In conjunction with the name change, Quince Therapeutics will launch a new corporate website and social media profiles on Twitter and LinkedIn, also effective August 1, 2022.